The "Win-Win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy

<p>Abstract</p> <p>Background</p> <p>Worldwide, breast cancer is the most frequent malignancy among females. Its incidence shows a trend towards an increase in the next decade, particularly in developing countries where less than of 5% of resources for cancer management are available. In most breast cancer cases systemic cancer treatment remains a primary management strategy. With the increasing costs of novel drugs, amidst the growing breast cancer rate, it can be safely assumed that in the next decade, newly developed cancer drugs will become less affordable and therefore will be available to fewer patients in low and middle income countries. In light of this potentially tragic situation, a pressing need emerges for science-based innovative solutions.</p> <p>Methods</p> <p>In this article, we cite examples of recently published researches and case management approaches that have been shown to lower overall treatment costs without compromising patient outcomes. The cited approaches are not presented as wholly inclusive or definitive solutions but are offered as effective examples that we hope will inspire the development of additional evidence-based management approaches that provide both efficient and effective breast cancer treatment</p> <p>Results</p> <p>We propose a "win-win" initiative, borne in the year of 2008 of strategic information sharing through preparatory communications, publications and our conference presentations. In the year 2009, ideas developed through these mechanisms can be refined through focused small pilot meetings with interested stakeholders, including the clinical, patient advocate, and pharmaceutical communities, and as appropriate (as proposed plans emerge), governmental representatives. The objective is to draw a realistic road map for feasible and innovative scientific strategies and collaborative actions that could lead to resource sparing; i.e. cost effective and tailored breast cancer systemic treatment for low and middle income countries.</p> <p>Conclusion</p> <p>The intended result would assure sustained affordability and accessibility in breast cancer systemic therapy for patients in low and middle income countries. As an added benefit, the example of breast cancer could be expanded to include other cancers in diverse settings around the world.</p

Carrier Line Technique for Downhole Chemical Injection in Oil and Gas Industry; Case Study: El Hamra Oil Company

In oil production companies, corrosion is a common issue with various adverse economic and environmental consequences. Active well production fluid always comprises inherently corrosive and highly corrosive substances. There are a variety of treatment techniques to prohibit corrosion, such as chemical treatment, cathodic protection, and paint-based corrosion inhibitors. El Hamra Oil Company produces crude oil from three main locations. The research group noticed several downhole localized corrosion problems in the artificial lift system. This paper presents a case study to quantify the extra operation cost of periodically replacing the entire tubing string, renting the pulling unit, and production deferring. The research quantifies the economic impacts after corrosion inhibitor is injected downhole using the carrier line technique (CLT). The results show that the company saved more than 672 K $ during three years of using downhole chemical treatment; dramatically decreasing the regular corrosion incidents in three active wells. The actual profits are expected to increase exponentially for the following years, meanwhile reducing the environmental impacts to meet Egypt’s strategy towards sustainable goals in 2030

Breast Radiation Therapy Guideline Implementation in Low- and Middle-income Countries

Radiation therapy plays a critical role in the management of breast cancer and often is unavailable to patients in low-and middle-income countries (LMCs). There is a need to provide appropriate equipment and to improve the techniques of administration, quality assurance, and use of resources for radiation therapy in LMCs. Although the linear accelerator is the preferred equipment, telecobalt machines may be considered as an acceptable alternative in LMCs. Applying safe and effective treatment also requires well trained staff, support systems, geographic accessibility, and the initiation and completion of treatment without undue delay. In early-stage breast cancer, standard treatment includes the irradiation of the entire breast with an additional boost to the tumor site and should be delivered after treatment planning with at least 2-dimensional imaging. Although postmastectomy radiation therapy (PMRT) has demonstrated local control and overall survival advantages in all patients with axillary lymph node metastases, preference in limited resource settings could be reserved for patients who have >= 4 positive lymph nodes. The long-term risks of cardiac morbidity and mortality require special attention to the volume of heart and lungs exposed. A]ternative treatment schedules like hypofractionated radiation and partial breast irradiation currently are investigational. Radiation therapy is an integral component for patients with locally advanced breast cancer after initial systemic treatment and surgery. For patients with distant metastases, radiation is an effective tool for palliation, especially for bone, brain, and soft tissue metastases. The implementation of quality-assurance programs applied to equipment, the planning process, and radiation treatment delivery must be instituted in all radiation therapy centers. Cancer 2008;113(8 suppl):2305-14. (C) 2008 American Cancer Societ